secwatch / observer
8-K filed June 5, 2026, 4:33 PM ET ticker EWTX CIK 0001710072
other confidence high sentiment neutral materiality 0.10

Edgewise Therapeutics stockholders elect three directors, ratify auditor, approve say-on-pay at 2026 annual meeting

Edgewise Therapeutics, Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.99

Edgewise Therapeutics, Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2026-06-04 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2026-06-04
Exact text from the filing
Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm For Against Abstain 99,637,228 1,123 578,031
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.98

Edgewise Therapeutics, Inc. shareholders approved Election of three Class II Directors at the 2026-06-04 meeting.

Proposal
director election
Outcome
passed
Meeting
2026-06-04
Exact text from the filing
Proposal 1: Election of three Class II Directors Name of Director For Withheld Laura Brege 87,300,827 3,822,867 Badreddin Edris, Ph.D. 64,082,681 27,041,013 Jonathan Root, M.D. 59,213,781 31,909,913
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.99

Edgewise Therapeutics, Inc. shareholders approved Advisory Vote on the Compensation of the Company's Named Executive Officers at the 2026-06-04 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2026-06-04
Exact text from the filing
Proposal 3: Advisory Vote on the Compensation of the Company's Named Executive Officers For Against Abstain 87,055,111 3,491,326 577,257
View on SEC.gov

995 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Edgewise Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001104659-26-071011
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.